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Abstract 
Iodoacetamide is perhaps the most widely used reagent for the alkylation of free sulfhydryls in 
proteomic experiments.  Here we report that both incomplete derivatization of Cys side-chains and 
overalkylation of the peptides may lead to the misassignment of glycoforms when LC-MS/MS with 
electron-transfer dissociation (ETD) alone is used for the structural characterization of glycopeptides.  
Accurate mass measurements do not help, because the elemental compositions of the misidentified 
and correct modifications are identical.  Incorporation of “higher-energy C-trap dissociation” (HCD), 
i.e. beam-type collision-induced dissociation data into the database searches with ETD data may 
prove decisive in most cases.  However, the carbamidomethylation of Met residues leads to 
sulfonium ether formation, and the resulting fixed positive charge triggers a characteristic 
fragmentation, that eliminates the normal Y1 fragment from the HCD spectra of N-linked 
glycopeptides, producing an abundant Y1-48 Da ion instead (the nominal mass diference is given 
relative to the unmodified amino acid sequence), that easily can be mistaken for the side-chain loss 
from Met sulfoxide.  In such cases, good quality ETD data may indicate the discrepancy, and will also 
display abundant fragments due to CH3-S-CH2CONH2 elimination from the charge-reduced precursor 
ions.  Our observations also draw attention to the underreported interference of different 
unanticipated covalent modifications. 
  
Introduction 
In most proteomic sample preparation protocols the denaturation of proteins is followed by 
reduction of the disulfide-bridges and by blocking the newly formed sulfhydryl groups in order to 
prevent reoxidation.  Perhaps the most frequently used alkylating agent is iodoacetamide 
(approximately 70% of the data deposited at PRIDE as of May 2015, were acquired from 
carbamidomethylated samples).  The length of the alkylation reaction varies.  Some protocols then 
will remove the reagent excess [1, 2]; some try to quench the alkylation reaction with the addition of 
DTT [3, 4]; others perform the in-solution digestion in the presence of the derivatizing agents [5, 6].  
As all chemical reactions, alkylation of Cys side-chains is not perfect either.  If the exposure was not 
long enough, or the protein was not properly denatured underalkylation does occur [7, 8].  At the 
same time, overalkylation also frequently happens [9-13].  Alkylation of the newly formed N-termini, 
Lys, His, Asp, and Met side-chains have been reported.  Obviously, both under- or overalkylation will 
cause problems in MS/MS data interpretation in large scale proteomic experiments.  Primarily, 
because it will prevent the identification of the affected sequences.  However, it also may result in 
misassignment of MS/MS data.  
Mass spectrometry is the method of choice for the analysis of post-translational modifications both  
in the characterization of individual proteins and in large scale, systems biology experiments [14].  
Mass spectrometry has been used in the characterization of extracellular glycosylation for decades, 
but usually the released glycan pool was characterized [15] or the formerly glycosylated peptides 
were identified [16].  There is growing evidence that glycosylation may influence biological processes 
in a site-specific manner [17-19], and thus, there is a growing need for the analysis of intact 
glycopeptides.  Recent technical developments, such as the introduction of electron-transfer 
dissociation (ETD) [20] and new, high sensitivity instrumentation equipped with ETD have made 
large scale glycopeptide analysis a reality [21, 22]. 
Our group has been involved in glycosylation analysis for almost a decade.  Recently we have been 
using wheat germ agglutinin-based lectin-affinity chromatography for glycopeptide enrichment from 
various tryptic digests.  The isolated mixtures have then been subjected to LC-MS/MS analysis, 
where both collisional and electron-transfer activation (beam-type CID (HCD), and ETD, respectively)  
have been used to reveal the identity of the glycopeptides.  Collisional activation of glycopeptides 
leads to extensive glycan and limited peptide fragmentation.  Ion trap CID spectra almost exclusively 
display fragments formed by glycosidic bond cleavages, while beam-type CID (HCD) data may feature 
sufficient information for the identification of the sequence modified [23].  The activation of multiply 
charged glycopeptide ions by electron-transfer leads to peptide backbone cleavages leaving the side-
chains intact in principal.  This is an advantage and a significant drawback at the same time, since a 
wide array of glycoforms may be present in each mixture analyzed [21, 24, 25].  In order to interpret 
such results, all potential glycans have to be considered as variable modifications, and thus, not only 
a protein, but also a glycan database has to be interrogated.  Among the available search engines 
Byonic is uniquely ‘specialized’ in glycopeptide analysis, and it contains default glycan databases that 
make this task relatively straightforward [26, 27].  Nevertheless since large-scale intact glycopeptide 
analysis is still in its infancy careful evaluation of the search results cannot be skipped. 
Here we present examples, when under- or overalkylation led to the misidentification of the glycan 
structures of glycopeptides in database searches with ETD data.  These examples again underscore 
that ETD data alone may not be sufficient for unambiguous glycopeptide identifications. 
 
Methods 
Mouse synaptosome sample 
“Thirty milligrams of synaptosome was resuspended in 1 ml buffer containing 50 mm ammonium 
bicarbonate, 6 M guanidine hydrochloride, 6× Phosphatase Inhibitor Cocktails I and II (Roche), and 
20 μM PUGNAc (Tocris). The mixture was incubated for one hour at 57 °C with 2 mM Tris(2-
carboxyethyl)phosphine hydrochloride to reduce cysteine side chains, these side chains were then 
alkylated with 4.2 mM iodoacetamide in the dark for 45 min at 21 °C. The mixture was diluted sixfold 
with ammonium bicarbonate to a final ammonium bicarbonate concentration of 100 mm and 1:50 
(w/w) modified trypsin (Promega, Madison, WI) was added. The pH was adjusted to 8.0 and the 
mixture was digested for 12 h at 37 °C. The digests were desalted using a C18 Sep Pak cartridge 
(Waters, Milford, MA) and lyophilized to dryness using a SpeedVac concentrator (Thermo Electron, 
San Jose, CA).” [28].  Glycopeptides were enriched by lectin-attinity chromatography using wheat 
germ agglutinin, and further fractionated by high pH reversed phase chromatography.  Each fraction 
was analyzed by LC-MS/MS using ETD as the activation method on an LTQ Orbitrap Velos on-line 
coupled to a Waters nanoAcquity UPLC.  The precursor ions were measured in the Orbitrap, the ETD 
data were acquired in the linear ion trap.  Supplemental activation for the ETD experiments was 
enabled.  These ETD data were interrogated using Protein Prospector v. 5.9.0; Mus musculus 
proteins in UniProt (downloaded 07/06/2011) were searched, a randomized sequence for each entry 
was added to the database; only tryptic cleavages were considered, one missed cleavage was 
permitted; mass accuracy required was 10 ppm and 0.6 Da, for the precursor ions and the 
fragments, respectively; carbamidomethylation of Cys residues was considered as fixed 
modification; while N-terminal Gln cyclization, Met oxidation, protein N-terminal acetylation and 
Ser/Thr fucosylation were listed as variable modifications, 3 modifications/peptide were permitted. 
The results were filtered using the following criteria: minimum score = 22, max E = 0.001, and 
precursor mass accuracy within 5 ppm [21]. 
Further details about the synaptosome preparation, and the fractionation of the digest have been 
published [21, 28]. 
Human serum sample 
Human serum samples were prepared with a slightly modified version of the FASP protocol [2].  One 
ml human serum was supplemented to give a final concentration of 50 mM DTT, 6M guanidine and 
50 mM Tris (pH:7.5), reduction was performed on 95 °C for 30 min, and 100 μl 200 mM 
iodoacetamide solution was added for the alkylation (30 min in the dark).  The reagent excess was 
removed, the buffer was replaced, the digestion proceeded and the resulting peptides were 
collected according to the published protocol (for further details see Supplement 1.).  Glycopeptides 
were enriched by lectin affinity chromatography using Concanavalin A followed by wheat germ 
agglutinin.  LC-MS/MS analyses of the resulting peptide mixtures were performed on an LTQ 
Orbitrap Elite mass spectrometer (Thermo Scientific LTD) on-line coupled to a Waters nanoAcquity 
UPLC.  Samples were injected onto a Waters Symmetry C18 trapping column (180μm* 20mm, 5μm 
particle size, 100Å pore size; Waters 186003514) and after trapping with 3% B for 5 minutes (flow 
rate: 5 μl/min) the peptide mixture was transferred to and separated on a Acclaim PepMap RSLC 
column (75μm*250mm, 2μm particle size, 100Å pore size; Dionex 164536) developing a linear 
gradient of 3-40% B in 55 min (flow rate: 300nl/min; solvent A: 0.1% formic acid/water, solvent B: 
0.1% formic acid/acetonitrile).  Mass measurements were performed in the Orbitrap, and the 3 most 
abundant multiply charged ions were selected for HCD analysis.  ETD data acquisition(performed in 
the linear ion trap) was triggered by the detection of the HexNAc oxonium ion, m/z 
204.0867±10ppm among the top 50 HCD fragments [29] (minimum signal intensity:100).  
Supplemental activation for the ETD experiments was enabled.  Normalized collision energy for HCD 
experiments was set to 32. MS/MS data of z=2 and z>2 charge states were acquired in separate 
experiments.  Proteome Discoverer (Thermo Scientific, v1.4.0.288) was used to generate peak lists 
from the raw data.  Database searches were performed with the ETD data using Byonic (v2.0-25, 
Protein Metrics Inc.) with the following parameter set: human subset of the Uniprot database 
(downloaded 11/13/2013, 39697 entries); tryptic peptides with maximum one missed cleavage, 
mass accuracies within 5 ppm and 0.6 Da for precursor and fragment ions, respectively.  Fixed 
modification was carbamidomethylation of Cys residues.  Variable modifications were Met oxidation 
(common, maximum 3 modifications/peptide); cyclization of N-terminal Gln residues (rare, 
maximum 1 modification/peptide); protein N-terminal acetylation (rare, maximum 1 
modification/peptide) and N-glycans (rare, maximum 1 modification/peptide using the “N-glycan 57 
human plasma” glycan set).  Decoy sequences were concatenated to forward entries and common 
contaminants (using the built-in “common contaminant” database of 69 proteins) were also 
considered.  Acceptance criteria: 2% false discovery rate on the protein level, minimum peptide 
score: 200. 
The sample preparation protocol for dataset PDX001277 from the PRIDE repository 
(http://www.ebi.ac.uk/pride/archive/) has been included in Supplement 2, where the appropriate 
search parameters for the preformed data analysis as well as the acceptance criteria are also listed.   
Experimental details about testing different alkylating agents with the FASP protocol are presented 
in Supplement 3. 
 
Results and discussion 
First we demonstrate how underalkylation may interfere with glycopeptide analysis.  We illustrate 
this point with a specific type of O-glycosylation.  O-linked glycans may feature different core 
structures, among them there is a deoxyhexose, fucose (Fuc).  We have reported that in a mouse 
synaptosome dataset numerous high scoring O-fucosyl peptides were detected (Table 1) [21].  
However, a consensus motif of CXXGGT/SC has been described for O-fucosylation [30], and none of 
the identified sequences fulfilled this requirement.  While one can always assume that the 
consensus motif definition should be more flexible, the only common denominator among the 
identified sequences was the presence of a Cys residue in proximity to the glycosylation site.  Once 
underalkylation is considered the explanation becomes obvious, the modifying glycan is HexNAc 
(GlcNAc or GalNAc) instead of the Fuc.  Figure 1 demonstrates the quality of the data as well as the 
difficulty to identify the misassignments.  The ETD spectrum features almost complete c and z. ion 
series, only the Thr-8’s c fragment is missing, while in the C-terminal series the Cys residue, not 
unexpectedly, produced a w fragment (Peptide fragmentation nomeclature [31]) instead of a z. ion 
[32] that does not reveal whether the side-chain was alkylated or not.  Not only the mass of HexNAc 
is the same as the two other modifications combined, but even their elemental compositions are 
identical: HexNAc = C8H13NO5 = C6H10O4 + C2H3NO = Fuc + carbamidomethyl group (the elemental 
compositions of the structures added to the peptide are listed).  Thus, only two fragments prove our 
conclusions: one is the result of the characteristic acetyl loss of N-acetylhexosamines, the other is 
formed by the loss of the modifying sugar, both from the charge-reduced precursor ion.  (Quite a 
few of the sequences listed in Table 1 were also detected with the HexNAc and properly 
carbamidomethylated [28]). 
One can presume that similar misassignments indicating the presence of a Fuc in the glycan and a 
carbamidomethyl group on the peptide instead of an additional HexNAc in the oligosaccharide also 
may happen in N-linked glycopeptides if the underivatized Cys is located sufficiently close to the 
glycosylation site.  We believe that this danger actually could be higher for N-glycan determination in 
any high-throughput studies since there may not be any obvious warning signs such the one we 
encountered in the O-glycosylation study described above.  At the same time, in both cases data 
obtained by collisional activation (either by ion trap or beam-type CID) easily could confirm the 
identity of the sequence modified in form of Y0 and Y1 fragments, for any O-linked or N-linked 
glycopeptide, respectively (nomenclature [33]) [34, 35]. 
On the same basis overalkylation also may lead to incorrect N-glycan composition assignments.  
Fucosylated structures with an additional carbamidomethyl group on the peptide may be 
misinterpreted as featuring a HexNAc instead of the Fuc.  Overalkylation represents a higher 
interference potential, since a series of amino acid side-chains may be derivatized [9-13].  However, 
if the site of modification is the N-terminus, or the side-chain of Lys, His, or Asp, collisional 
dissociation could come to the rescue, and will reveal the molecular mass of the sequence modified, 
and thus, also the +57.0216 Da discrepancy. 
Here we will present an example, where spotting the problem may not be so trivial.  In a recent 
human glycopeptide study different glycoforms of tryptic peptide 74TVLTPATNHMGN*VTFTIPANR94 
of Complement 3 protein were identified (Asn-85, the glycosylation site is labeled with an asterisk).  
Oligomannose structures, GlcNAc2Man4-7 as well as hybrid oligosaccharides, GlcNAc3Hex3-6 were 
among the glycans assigned from the ETD data.  Some of the glycopeptides featured Met-83 
oxidized.  While evaluating the assignments we noticed a peculiar phenomenon.  i) The glycoforms 
with the hybrid glycans were only detected with the Met oxidized;  ii) in the HCD spectra of these 
peptides Y1 was not detected at all, only the corresponding fragment without the oxidized Met side-
chain (CH3SOH loss = -63.9983 Da) was abundant.  Appropriate peptide fragment ions if detected 
were also observed in this ‘truncated’ form, i. e. with an α-amino-3,4-dehydrobutyric acid instead of 
the methionine (Figure 2, Supplemental Figure 1).   
In this particular sequence the glycosylation site and the Met-sulfoxide are separated by only one 
residue.  Thus, an interaction between the oxidized side-chain and the glycan could not be excluded 
per se.  However, we could not find any other Met(O)-containing glycopeptide that displayed similar 
behavior.  The HCD spectra of such peptides always featured the ‘normal’ Y1 fragment as well as the 
product of the neutral loss of CH3SOH (-64 Da), and the intact Y1 was usually more abundant 
(Supplemental Figure 2).   
Thus, we started to search for a more plausible explanation.  Our hypothesis was that Met-83 was 
carbamidomethylated, not oxidized.  We have demonstrated long time ago that beta-elimination-
like partial side-chain loss is the favored fragmentation step for Met-sulfonium ethers [36] and also 
described in detail the CID characteristics of carbamidomethyl-methionine-containing peptides [37].  
The diagnostic fragmentation step there is the loss of CH3-S-CH2CONH2, i.e. -105.0249 Da that will 
transform the Met residue into a α-amino-3,4-dehydrobutyric acid (see Supplemental Figure 1B).  
The characteristic CH3SOH loss (-64 Da) from an oxidized methionine yields the same fragment 
(Supplemental Figure 1B). 
If the Met side-chain is carbamidomethylated instead of oxidized, then the peptide mass is 41 Da 
higher, thus, the glycan structure has to be so much lighter.  The mass difference between a HexNAc 
and a Hex is 41.0265 Da, and the elemental composition of the new structural combination will be 
exactly the same as the old one: oxidation of Met + HexNAc in the glycan = O + C8H13NO5 = C8H13NO6 
= C2H3NO + C6H10O5 = carbamidomethyl on the peptide + Hex in the glycan.  Once we scrutinized the 
ETD data in this light it becomes obvious that the fragmentation of Met-sulfonium ether has not 
been completely eliminated by the different activation method.  On the contrary, the most abundant 
fragments in the ETD spectra are the 58 and 105 Da losses from the charge-reduced precursor ion 
(Figure 3), i.e. either the carbamidomethyl group is removed (CH2CONH2 = 58.0293 Da) or, just like in 
the CID experiments, CH3-S-CH2-CONH2 is eliminated (-105.0249 Da).  Moreover, c11(2+) at m/z 598.8 
indicates carbamidomethylation of the N-terminal part of the peptide sequence.  In addition, we 
also discovered two shorter isoforms of the same sequence stretch, featuring Lys or Arg instead of 
Thr in position-89.  Both of these shorter sequences produced a z5
. fragment, clearly confirming that 
Asn-85 is modified with a GlcNAc2Man6 structure and Met-83 is carbamidomethylated (Figure 4).  
Based on the peak areas of the extracted ion chromatograms of the unmodified, Met-oxidized and 
Met-carbamidomethylated variants of the Complement C3 [74-94] GlcNAc2Man6 glycoform 
(Supplemental Figure 4) we estimated that the extent of Met-carbamidomethylation was 
approximately 7.6 %. 
In order to investigate the occurrence of overalkylation in other datasets, we selected a project from 
the PRIDE repository where the only covalent modification intentionally introduced was the 
carbamidomethylation of Cys residues (PXD001277).  In this project the reduction and alkylation was 
followed by an overnight in-solution digestion without removing the reagent excess (the 
experimental details provided with the dataset were included in Supplement 2.).  Reanalyzing 5 files 
from this dataset we found that more than 10% of the spectra assigned represented overalkylated 
sequences (Supplement 2).  We also performed experiments with iodoacetamide and 
N-ethylmaleimide as the alkylating agents using the FASP protocol [2], where the reagent excess is 
removed prior to the digestion.  Depending on the experimental conditions, 1-7% of the confidently 
identified peptides represented overalkylated peptides (Supplement 1 and 3). Overalkylation was 
detected even when only ~100-fold excess of the alkylating agent was applied (Supplement 1).  
Based on these data we believe overalkylation regularly occurs in high throughput proteomic 
experiments.  
 
Summary 
Mass spectrometry, a relatively unbiased analytical tool is widely used for post-translational 
modification (PTM) analysis including site-specific glycosylation analysis of single proteins as well as 
very complex mixtures.  Glycosylation is an ‘umbrella PTM’.  In each extracellular glycopeptide 
analysis per definition numerous different modifications have to be considered for each potential 
site, unless the suite of glycans present has been characterized prior to the glycopeptide analysis.  
Recently both single glycoprotein characterizations and high-throughput glycosylation studies rely 
heavily on beam-type CID (HCD) and ETD analysis of glycopeptides in line with automated data 
interpretation.  Although there have been attempts to connect the information content of data 
acquired by the different activation methods it has not got far enough [38, 39].  Our findings 
underscore the need for further software development for more reliable glycopeptide 
interpretation.  In addition, we also would like to draw attention to the interference of different 
covalent modifications that we believe is more common than reported. 
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Table 1 A few sequences identified as O-fucosylated from ETD data acquired from a mouse 
synaptosome tryptic digest (full, detailed list in ref. [21]). 
Peptide Score1 Expect1 
APSC(Carbamidomethyl)S(Fuc)GLSMVSGARPGPGPAATTHK 49.2 6.90E-08 
VC(Carbamidomethyl)S(Fuc)AAPPSVLNETGFSLTVPASAK 44.6 3.90E-06 
NAEGSTVT(Fuc)C(Carbamidomethyl)TGSIR 53.2 7.40E-06 
NQSLPVMMGSFGAPVC(Carbamidomethyl)T(Fuc)TSPK 37.4 3.80E-05 
VTPSLNSAPAPAC(Carbamidomethyl)S(Fuc)STSHLK 47.7 2.70E-05 
LDFGQGSGS(Fuc)PVC(Carbamidomethyl)LAQVK 55.8 4.60E-07 
QKAPFPAT(Fuc)C(Carbamidomethyl)EAPSR 42.5 4.80E-05 
FPFGSSC(Carbamidomethyl)T(Fuc)GTFHPAPSAPDK 37.8 6.30E-07 
IQTDT(Fuc)C(Carbamidomethyl)HSTVVHSPEVYSVIIR 51.4 1.50E-06 
YPATC(Carbamidomethyl)VT(Fuc)DIMLSHK 43.2 3.00E-06 
LGPVYC(Carbamidomethyl)QAS(Fuc)FSGTNIIGNK 39.6 5.30E-06 
AAT(Fuc)C(Carbamidomethyl)FSTTLTNSVTTSSVPSPR 41.2 1.00E-06 
1Both the score and the E-values refer to the incorrectly assigned structures.  In the correct 
assignments the sequences are modified with a HexNAc, and the Cys is not alkylated. 
  
Figure Legends 
 
Figure 1.  ETD spectrum of m/z 533.5834(3+) incorrectly identified as 
NAEGSTVT(Fuc)C(Carbamidomethyl)TGSIR.  In the correct assignment the Cys is not alkylated and 
the peptide is modified with a HexNAc.  The detected fragments are identical for both structures as 
shown in the scheme under the spectrum.  Only the characteristic 42 Da (Ac) and 203 Da (HexNAc) 
losses, both from the charge-reduced precursor ion, help to identify the glycan.  Peptide fragments 
are assigned according to Biemann [31].  The asterisk indicates a z+1 fragment.   
 
Figure 2.  HCD data of precursor masses, 913.1652(4+) (upper panel), and 923.4220(4+) (lower 
panel) that were identified from ETD data as 74TVLTPATNHM(Oxidized)GNVTFTIPANR94  glycoforms 
with an oligomannose (GlcNAc2Man6) and a hybrid (GlcNAc3Hex5) structure.  Peptide fragments 
retaining the core GlcNAc (exact additive mass: 203.0794) are indicated with the mass increment: 
+203.  The assignment of the second glycoform is incorrect.  When correctly assigned this 
glycopeptide features the same GlcNAc2Man6 structure as the first, but the Met residue is 
carbamidomethylated, not oxidized.  The fragmentation patterns for the two different assignments 
are presented in Supplemental Figure 1.   
 
Figure 3.  ETD spectrum of  TVLTPATNHM(Carbamidomethyl)GN(GlcNAc2Man6)VTFTIPANR, precursor 
ion at m/z 923.4220(4+) within 3 ppm of the calculated value.  Losses characteristic of the Met-
sulfonium ether are labeled in red.  Either the carbamidomethyl group is removed (-58 Da) or CH3-S-
CH2-CONH2 (-105) is eliminated.  The fragmentation pattern is shown under the spectrum. 
Carbohydrate units are labeled following the CFG nomenclature: 
(http://www.functionalglycomics.org/static/consortium/Nomenclature.shtml) 
 
 
Figure 4.  ETD data of the shorter Complement 3 [74-89] isoforms with Arg (upper panel) and Lys 
(lower panel) in position 89, precursor ions at m/z 799.3546(4+) and m/z 792.3521(4+), respectively, 
both within 2 ppm of the calculated values.  These data confirmed the GlcNAc2Man6 glycan 
structure, and also indicated that Met-83 is carbamidomethylated.  Losses characteristic of the Met-
sulfonium ether are labeled in red.  Either the carbamidomethyl group is removed (-58 Da) or CH3-S-
CH2-CONH2 (-105) is eliminated.  The fragmentation pattern is presented under the spectra, 
fragments in bold were detected in both spectra, fragments underlined were detected only in the 
spectrum of the peptide with the C-terminal Lys (lower panel).  Carbohydrate units are labeled 
following the CFG nomenclature: 
(http://www.functionalglycomics.org/static/consortium/Nomenclature.shtml). 
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